<DOC>
	<DOCNO>NCT01714037</DOCNO>
	<brief_summary>Part A study investigate Maximum Tolerated Dose Debio 0932 combination standard care chemotherapy first- second-line treatment advance NSCLC .</brief_summary>
	<brief_title>A Clinical Study Safety Efficacy Debio 0932 Combination With Standard Care Patients With Non-small Cell Lung Cancer NSCLC</brief_title>
	<detailed_description>Part A study determine Maximum Tolerated Dose Debio 0932 combination cisplatin/pemetrexed cisplatin/gemcitabine treatment-naïve patient Stage IIIb IV NSCLC , docetaxel previously treat patient Stage IIIb IV NSCLC . Escalating dos Debio 0932 give subsequent patient combination standard dose 3 background chemotherapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis NSCLC confirm squamous nonsquamous tumour histology , without know epidermal growth factor receptor ( EGFR ) mutation Advanced metastatic disease ( Stage IIIb IV ) Patients treated cisplatin/gemcitabine cisplatin/pemetrexed : No previous systemic treatment chemotherapy , target therapy investigational agent ( except adjuvant therapy &gt; 6 month ago ) ; Patients treat docetaxel : ≥ 1 previous treatment chemotherapy Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ECOG performance score 01 Life expectancy ≥ 3 month Adequate bone marrow , renal hepatic function LVEF ≥ 55 % cardiac ultrasound Symptomatic brain metastasis Gastrointestinal disorder could affect drug absorption ( include , limit , major abdominal surgery , significant bowel obstruction , ulcerative colitis , Crohn 's disease ) Concurrent treatment systemic anticancer therapy Serious concomitant uncontrolled medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>HSP90</keyword>
	<keyword>Debio 0932</keyword>
	<keyword>Standard care treatment , NSCLC</keyword>
</DOC>